Promoted Content Promoted Content

X

Find the latest Drugs in Development and Pipeline Prospector News of Fermion Oy.

  • Webinars & Exhibitions

  • Benserazide Hydrochloride

  • Dexmedetomidine Hydrochloride

  • Methotrexate

  • Nintedanib Esylate

  • Liquid Drug Product Manufacturing

  • API Contract Manufacturing Services

  • Controlled Substance Manufacturing

  • Hormonal & Non-Hormonal Creams & Ointments

  • Contract Manufacturing for Cytotoxic APIs

  • CMO for Hormonal Gels & Solutions

PharmaCompass
Fermion VB RM
Fermion Oy
Finland Flag
Country
Country
Finland
Address
Address
Koivu-Mankkaan tie 6 A, FI-02200 Espoo
Telephone
Telephone
+358 10 4261
Twitter
Twitter
Contact Info
Others

Details:

Nubeqa (darolutamide) is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells.


Lead Product(s): Darolutamide,Docetaxel

Therapeutic Area: Oncology Product Name: Nubeqa

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Bayer AG

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 23, 2023

Fermion Orion Company Banner

PharmaLytica 2023

Not Confirmed

envelop Contact Supplier

Details:

Nubeqa (darolutamide) is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells.


Lead Product(s): Darolutamide,Docetaxel

Therapeutic Area: Oncology Product Name: Nubeqa

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 20, 2023

Fermion Orion Company Banner

PharmaLytica 2023

Not Confirmed

envelop Contact Supplier

Details:

Nubeqa (darolutamide) is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells.


Lead Product(s): Darolutamide,Docetaxel

Therapeutic Area: Oncology Product Name: Nubeqa

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 01, 2023

Fermion Orion Company Banner

PharmaLytica 2023

Not Confirmed

envelop Contact Supplier

Details:

Nubeqa (darolutamide) is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells.


Lead Product(s): Darolutamide,Docetaxel

Therapeutic Area: Oncology Product Name: Nubeqa

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Bayer AG

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 27, 2023

Fermion Orion Company Banner

PharmaLytica 2023

Not Confirmed

envelop Contact Supplier

Details:

Nubeqa (darolutamide) is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells.


Lead Product(s): Darolutamide,Docetaxel

Therapeutic Area: Oncology Product Name: Nubeqa

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 27, 2023

Fermion Orion Company Banner

PharmaLytica 2023

Not Confirmed

envelop Contact Supplier

Details:

Abiraterone acetate is a medication used to treat prostate cancer. Specifically it is used together with a corticosteroid for metastatic castration-resistant prostate cancer and metastatic high-risk castration-sensitive prostate cancer.


Lead Product(s): Abiraterone Acetate

Therapeutic Area: Oncology Product Name: Abiraterone Acetate-Generic

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: Amneal Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 04, 2023

Fermion Orion Company Banner

PharmaLytica 2023

Not Confirmed

envelop Contact Supplier

Details:

Levosimendan (TNX-102 and TNX-103) is a unique potassium ATP channel activator and calcium sensitizer that affects the heart and vascular system through multiple mechanisms of action.


Lead Product(s): Levosimendan

Therapeutic Area: Cardiology/Vascular Diseases Product Name: TNX-102

Highest Development Status: Phase IIProduct Type: Small molecule

Recipient: Tenax Therapeutics

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 10, 2022

Fermion Orion Company Banner

PharmaLytica 2023

Not Confirmed

envelop Contact Supplier

Details:

Nubeqa (darolutamide) is an oral androgen receptor inhibitor with a unique chemical structure developed to inhibit the growth of cancer cells. FDA has approved its use in combination with docetaxel for treating metastatic hormone-sensitive prostate cancer.


Lead Product(s): Darolutamide,Docetaxel

Therapeutic Area: Oncology Product Name: Nubeqa

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 08, 2022

Fermion Orion Company Banner

PharmaLytica 2023

Not Confirmed

envelop Contact Supplier

Details:

ODM-208 is an oral, non-steroidal inhibitor of CYP11A1 currently being evaluated in a Phase 2 clinical trial for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).


Lead Product(s): ODM-208,Glucocorticoid,Fludrocortisone Acetate

Therapeutic Area: Oncology Product Name: ODM-208

Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: MSD Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: $290.0 million

Deal Type: Collaboration July 13, 2022

Fermion Orion Company Banner

PharmaLytica 2023

Not Confirmed

envelop Contact Supplier

Details:

The research collaboration is based on new innovations that would improve the structure of the CAR T cell preparation. Cancer immunotherapy and one of its implementation methods, CAR T cell therapy, have brought completely new possibilities to cancer treatment.


Lead Product(s): CAR T-cell Therapy

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy

Recipient: Veripalvelu

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 08, 2022

Fermion Orion Company Banner

PharmaLytica 2023

Not Confirmed

envelop Contact Supplier
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY